## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($201.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Los Angeles jury orders Johnson & Johnson to pay $40 million over talc cancer claims**
- Source: Class Action Lawsuits | 20251229T150539 | Bearish | Relevance: 100%
- A Los Angeles jury has ordered Johnson & Johnson to pay $40 million in compensatory damages in a bellwether talc trial. The verdict stems from claims that J&J's talc products were a "substantial factor" in two women developing ovarian cancer. Although J&J was found liable for negligence, negligent failure to warn, and false representation, the jury declined to award punitive damages, finding no malice, fraud, or oppression.

**2. Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies**
- Source: Yahoo Finance | 20251229T130829 | Bullish | Relevance: 100%
- Johnson & Johnson has completed the acquisition of Halda Therapeutics for $3.05 billion in cash, integrating Halda's proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACâ„¢) platform. This acquisition enhances Johnson & Johnson's oncology pipeline with HLD-0915, a clinical-stage therapy for prostate cancer designed to overcome treatment resistance, and other early-stage candidates for various solid tumors. The deal is expected to cause dilution in Johnson & Johnson's Q4 2025 and 2026 earnings due to non-recurring charges and integration costs.

**3. Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of "Moderate Buy" from Brokerages**
- Source: MarketBeat | 20251228T070826 | Bullish | Relevance: 100%
- Johnson & Johnson (NYSE:JNJ) has received a consensus "Moderate Buy" rating from 27 brokerages, with an average 1-year target price of $210.25. Institutional investors have significantly increased their holdings, with Norges Bank and Laurel Wealth Advisors making substantial new or increased investments. The company maintains a strong financial position with a market cap of $500.02 billion, a P/E ratio of 20.03, and pays a quarterly dividend of $1.30 per share.

**4. Top 5 High-Yield S&P 500 Stocks to Buy for 2026**
- Source: Finviz | 20251229T184351 | Bullish | Relevance: 90%
- This article identifies five high-yield S&P 500 stocks poised for growth in 2026, considering macroeconomic uncertainties, geopolitical volatility, and the increasing investment in AI infrastructure. The shortlisted companies are International Business Machines (IBM), Analog Devices (ADI), Johnson & Johnson (JNJ), The Gap (GAP), and Hewlett Packard Enterprise (HPE), all noted for strong fundamentals, dividend yields, and relevance to emerging market trends. The article outlines key growth drivers for 2026, including rapid AI buildouts, while also addressing challenges like tariff-related uncertainties and stable interest rates.

**5. Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025**
- Source: Sentinel-Standard | 20251228T000853 | Somewhat-Bullish | Relevance: 74%
- Protagonist Therapeutics announced that data from its Phase 2b ANTHEM-UC study for icotrokinra in ulcerative colitis will be presented at the United European Gastroenterology Week Berlin 2025. The presentation will detail the week 12 results from the randomized, double-blind, placebo-controlled, treat-through, dose-ranging trial. Icotrokinra is an investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 18.0x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $500.1B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.0 |
| Current P/E | 19.1 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.67), momentum weakening. RSI neutral at 56. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.25% (CS: 27) | Neutral |
| RSI_14 | 56.5 | Neutral |
| MACD Histogram | -0.67 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.197x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $207.58
- **Stop Loss:** $201.04 (3.2% risk)
- **Target:** $214.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 211
- **Position Value:** $43,799.38
- **Portfolio %:** 43.80%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*